MARKET

GENE

GENE

Genetic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.230
-0.180
-7.47%
Closed 19:59 07/06 EDT
OPEN
2.390
PREV CLOSE
2.410
HIGH
2.405
LOW
2.220
VOLUME
707.63K
TURNOVER
--
52 WEEK HIGH
5.36
52 WEEK LOW
1.408
MARKET CAP
19.01M
P/E (TTM)
-4.8143
1D
5D
1M
3M
1Y
5Y

EPS

GENE News

More
Genetic Technologies CEO to Participate in Investor Webinar and Q&A Session on June 24, 2020
GlobeNewswire · 06/23 13:00
US Patent Office Grants Key Risk Test Patent
GlobeNewswire · 06/18 13:00
Genetic Technologies nabs new patent in assessing risk of breast cancer
Seeking Alpha - Article · 06/18 12:28
Genetic Technologies Reports Issued US Patent No. '549 'Methods for assessing risk of developing breast cancer'
Molecular diagnostics company Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE) (the “Company”) is pleased to announce the issuance of US Patent No: US 10,683,549, Methods for assessing risk of developing
Benzinga · 06/18 12:14
U.S. Patent Office Grant sGenetic Technologies A Key Risk Test Patent
US Patent Office Grants Key Risk Test Patent Issuance of US Patent No: US 10,683,549, Methods for assessing risk of developing breast cancer. Filed provisional patent for its COVID-19 Severity Risk Test, 2020901739
Benzinga · 06/18 12:06
Genetic Technologies Granted US Patent Titled 'Methods for assessing risk of developing breast cancer'
Benzinga · 06/16 13:40
Insider Buying: The Genetic Technologies Limited (ASX:GTG) Independent Non-Executive Chairman Just Bought 24% More Shares
Simply Wall St. · 06/04 21:49
Genetic Technologies Announces Closing of $8.0 Million Public Offering
GlobeNewswire · 05/29 02:00

Industry

Healthcare Facilities & Services
+3.80%
Healthcare Providers & Services
+1.99%

Hot Stocks

Symbol
Price
%Change

About GENE

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.
More

Webull offers kinds of Genetic Technologies Limited (ADR) stock information, including NASDAQ:GENE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GENE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GENE stock methods without spending real money on the virtual paper trading platform.